Found 9 matching trials
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) PHASE3 This study was an international, multi-center, randomized, double-blind, pl...
Show More Location
University of Alabama-Birmingham
Learn More & Join Trial
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) PHASE3 This study is an international, multi-center, randomized, double-blind, pla...
Show More Location
University of Alabama Birmingham
Learn More & Join Trial
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH PHASE2 This is a multicenter, single-arm trial to evaluate the safety of the trans...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension N/A This was a multicenter, prospective, observational, open-label study. Patie...
Show More Location
University of California, Los Angeles
Learn More & Join Trial
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil PHASE1 The purpose of this study is to assess the effect of BIA 5-1058 200 mg on t...
Show More Location
PAREXEL International - Early Phase Clinical Unit
Learn More & Join Trial
Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients PHASE2 Patients undergoing orthotopic liver transplant will experience some degree...
Show More Location
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Learn More & Join Trial
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension PHASE4 This is a multicenter, open-label trial to evaluate the safety of continued...
Show More Location
Beijing Chao-Yang Hospital
Learn More & Join Trial
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension PHASE4 This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Tit...
Show More Location
Beijing Chao-Yang Hospital
Learn More & Join Trial
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients PHASE4 TripleTRE investigates the effect of initial triple combination therapy (or...
Show More Location
Ordensklinikum Linz
Learn More & Join Trial